2026-04-25T12:38:20Z https://www.pub.unibl.org/oai

oai:pub.unibl.org:30875 2025-12-19T04:43:51Z

Sorafenib as first line treatment for advanced liver cancer - are expiries https://www.unibl.org/sr-lat/fis/zaposlen/3371-zdenka-gojkovic https://www.unibl.org/sr-lat/fis/zaposlen/3512-sasa-jungic /unibl/author/Ivanka Rakita /unibl/author/Živko Vranješ /unibl/author/Radmila Rašeta /unibl/author/G. Marić /unibl/author/M. Vještica /unibl/author/S. Mijatović /unibl/author/P. Dašić /unibl/author/M. Vižin /unibl/author/Jelena Rožić 2012 Conference Paper text /unibl/sci/idNaucniRad:25647 Annals of Oncology Annals of Oncology 2012; 23(4) iv57 Annals of Oncology 2012; 23(4) iv57 Z. Gojković, S. Jungić, I. Rakita, Ž. Vranješ, R. Rašeta, G. Marić, M. Vještica, S. Mijatović, P. Dašić, M. Vižin, J. Rožić, Sorafenib as first line treatment for advanced liver cancer - are expiries, Annals of Oncology 2012; 23(4) iv57, 2012 https://www.pub.unibl.org/s/cir/item/30875